
Opinion|Videos|April 19, 2024
Ruxolitinib and Ibrutinib for the Treatment of Chronic Graft-versus-Host Disease
This segment delves into the management of a case of moderate cGvHD involving the skin, eyes, and mouth, with a focus on the use of Belumosudil based on the ROCKstar trial data.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
FDA Oncology Update January 2026: New Horizons in Precision Medicine
5



















